Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05692635 · ClinicalTrials.gov registry record · Phase 2
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
A Phase 2 study of Brain Metastases and Nonsmall Cell Lung Cancer Stage III, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05692635 is a Phase 2 study of Brain Metastases and Nonsmall Cell Lung Cancer Stage III that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 60 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05692635, a Phase 2 study of Brain Metastases and Nonsmall Cell Lung Cancer Stage III, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Conditions Studied
Interventions
- OTHER Blood draws
- DRUG Gadolinium
- DIAGNOSTIC_TEST MRI of the Brain
- OTHER Quality of Life Questionnaires
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05692635
The ClinicalTrials.gov registry entry for NCT05692635 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (72% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Metastases appearing as the primary indexed condition, and to 4 interventions - of which Blood draws is the first listed.
NCT05692635 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05692635 about?
NCT05692635 is a clinical study titled "Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance". The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
What is the current status of trial NCT05692635?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-08-30. Estimated completion is 2028-04.
What conditions does trial NCT05692635 study?
This clinical trial studies the following conditions: Brain Metastases, Nonsmall Cell Lung Cancer Stage III.
What interventions are being tested in trial NCT05692635?
The interventions under investigation include: Blood draws (OTHER), Gadolinium (DRUG), MRI of the Brain (DIAGNOSTIC_TEST), Quality of Life Questionnaires (OTHER).
Who is sponsoring clinical trial NCT05692635?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05692635 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
RECRUITING · Phase 2
Explore more on PlainTrial
Brain Metastases
All registered trials for this condition
Nonsmall Cell Lung Cancer Stage III
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.